# A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Source: https://onco.cc/trials/nct06514794/  
OnCo record `nct06514794` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of WU-CART-007 in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Allotera Therapeutics, now recruiting.

## Summary

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) is a phase 2 interventional study registered as NCT06514794 by Allotera Therapeutics, with 125 participants planned, started 2025-01-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: WU-CART-007.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06514794
- Phase: 2
- Setting: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
- Sponsor: Allotera Therapeutics
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT06514794: https://clinicaltrials.gov/study/NCT06514794

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Allotera Therapeutics (formerly Wugen)](https://onco.cc/companies/allotera-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06514794.json